Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
**Patient Story – Oleg’s Cancer Journey:**
Today, we share the story of a 46-year-old patient from Russia named Oleg. Oleg was diagnosed with follicular lymphoma and, after multiple rounds of chemotherapy, achieved complete remission. Unfortunately, the disease relapsed, with several enlarged lymph nodes appearing in his abdomen and other areas. Faced with this resurgence, Oleg was determined not to give up and decided to seek new treatment options to improve his quality of life.
**Tailor-Made CAR-T Treatment Plan:**
After extensive research, Oleg contacted us and connected with lymphoma experts from our Advanced Medicine in China team. Through video consultations and detailed discussions, he decided to pursue CAR-T cell therapy. With confidence in the potential of Chinese CAR-T therapy, Oleg and his family traveled thousands of miles to China to begin his CAR-T treatment journey.
Given Oleg’s high tumor burden and relapse after chemotherapy, the Chinese medical team customized a bridging therapy for him, combining targeted drugs with low-dose radiotherapy to reduce the tumor burden and improve the immune environment. Special care was taken when designing the radiotherapy plan, as Oleg still had fertility concerns. The team created a personalized treatment plan that balanced safety and effectiveness. During the treatment process, Oleg experienced almost no significant side effects, demonstrating excellent treatment compliance and tolerance. He maintained a strong relationship of trust and communication with the medical team.
**Complete CR – A New Life After Treatment**
Oleg’s CAR-T cell infusion process went smoothly. Despite a history of migraines, he only experienced mild headaches and low-grade fever after the treatment. Under the meticulous care of the treatment team, the CAR-T cells demonstrated strong anti-tumor effects, with minimal side effects. For a patient with a high tumor burden, he only developed grade 1 cytokine release syndrome (CRS), and his blood counts began to recover about a week after the infusion. Overall, he remained in good condition.
Fifteen days after the CAR-T infusion, an abdominal ultrasound showed significant shrinkage of the enlarged lymph nodes. Three months later, a PET-CT scan brought even more surprising news—Oleg’s tumors had completely disappeared, and his response was evaluated as a complete remission (CR). This meant that Oleg had beaten cancer!
Today, Oleg is doing better and better, running daily. He is especially grateful for the support and care provided by the Advanced Medicine in China team and the Chinese experts. Despite being far from home, he never felt inconvenienced during his treatment in China. The doctors and nurses not only communicated with him patiently but also provided significant help in his daily life.
**Why Choose CAR-T Treatment in China?**
CAR-T therapy has shown remarkable efficacy in treating relapsed and refractory follicular lymphoma, with clinical data showing an objective response rate (ORR) of over 90% and a median duration of response exceeding three years! Oleg’s case is a testament to China’s advanced medical technology. Traditional chemotherapy tends to lose effectiveness after repeated treatments, while CAR-T therapy offers the possibility of curing diseases like follicular lymphoma, which were previously considered incurable.
For patients like Oleg, who seek a high-quality life, China’s CAR-T therapy is bringing new hope. 
**World-Class – China’s CAR-T Indications and Beyond**
Today, China’s CAR-T is not only actively involved in global research but is also leading many developments in the CAR-T field. For patients like Oleg with follicular lymphoma, only China and the U.S. have approved CAR-T products targeting this condition. However, China’s CR rate is notably higher.
Currently, China offers the most extensive range of CAR-T indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for first-line, second-line, or third-line treatment failures or relapse; relapsed follicular lymphoma (FL) after second-line treatment; mantle cell lymphoma (MCL) with multiple treatment failures; unspecified DLBCL; large B-cell lymphoma transformed from FL; primary mediastinal large B-cell lymphoma; and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #AdvancedMedicineInChina #Lymphoma #FollicularLymphoma #CancerRemission #MedicalTourism #ChinaCare #HealingJourney #CancerFree #Immunotherapy #GlobalHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China？
# What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China?
Lymphoma
#CART #Lymphoma #DLBCL #LBCL #MedicalTourism #FL #MCL
In recent years, CAR-T cell therapy has sparked a revolution in cancer treatment worldwide, achieving remarkable results, especially in lymphoma care. As one of the global leaders in CAR-T therapy, China has attracted a large number of international patients seeking this cutting-edge immunotherapy. So, what types of lymphoma patients are suitable to travel to China for this advanced treatment?
## Indications: The First Choice for Relapsed or Refractory Lymphoma Patients
CAR-T treatment in China primarily targets patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Specific patient groups that are suitable include:
1. **Relapsed DLBCL**: Patients who did not respond to first-line treatments, such as R-CHOP, or relapsed within 12 months after treatment.
2. **Follicular Lymphoma (FL)**: Patients with grade 1-3a FL who have relapsed or are refractory after at least two lines of treatment.
3. **Mantle Cell Lymphoma (MCL)**: Patients whose disease remains difficult to control even after multiple treatments, including BTK inhibitors.
4. Patients whose lymphoma is resistant to traditional treatments or who experience rapid relapse after therapies such as conventional chemotherapy and targeted treatments.
5. More indications include diffuse large B-cell lymphoma (not otherwise specified), DLBCL transformed from follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, as well as grade 3b follicular lymphoma.
CAR-T therapy offers new hope to these patients by targeting the CD19 antigen on the surface of tumor cells.
## Physical Condition: Stable Health is Key
While CAR-T therapy has shown significant efficacy, the potential for serious side effects, such as **cytokine release syndrome (CRS)** and **neurotoxicity**, means that patients must be in stable health to tolerate the risks associated with treatment. Suitable patients should meet the following conditions:
– **Good heart and lung function**: The patient’s cardiovascular and respiratory health should be adequate to handle the stress of treatment.
– **Normal liver and kidney function**: Liver enzymes (such as ALT) and creatinine levels should be within normal ranges to ensure that the patient can properly eliminate toxins from the body.
– **Stable immune system**: Patients should not have severe infections or immunosuppressed conditions, as CAR-T therapy can further weaken the immune system, increasing the risk of infection.
Additionally, patients need to achieve a performance status score of 0-1 on the ECOG scale, indicating that they have good functional ability and can handle daily activities independently.
## Pre-Treatment Testing: Ensuring Proper Antigen Expression
CAR-T therapy targets specific antigens (such as CD19) on the surface of tumor cells, so patients’ cancer cells must express these antigens for treatment to be effective. If tests show that the tumor cells do not express the relevant antigens, CAR-T therapy will not work effectively.
## Costs and Resources: The Advantages of CAR-T in China
Compared to Western countries, CAR-T therapy in China is relatively affordable, usually costing between hundreds of thousands to one million RMB, whereas in the U.S., CAR-T treatment can cost several hundred thousand dollars. For patients with the financial ability but who find it difficult to bear the high costs of treatment in the West, China offers a significant cost advantage.
Moreover, China boasts several top-tier hospitals with established CAR-T treatment programs, such as leading cancer centers in Beijing, Shanghai, and Guangzhou. These hospitals have extensive clinical experience, offering international patients convenient access to treatment.
## Contact Us:
The Advanced Medicine in China team has a wealth of connections with doctors and hospitals, enabling us to quickly help you find the most suitable hospital and expert team for your specific needs. In China, we provide a fast-track option for CAR-T treatment.
## Conclusion
With its cost advantages, advanced medical resources, and broad indications, CAR-T therapy in China has attracted a large number of international lymphoma patients. For those who have failed traditional treatments, are in good physical condition, and have sufficient financial means, CAR-T treatment in China is an ideal choice. If you or someone close to you meets these conditions, consider coming to China for world-leading CAR-T therapy, and open the door to new hope in the fight against cancer.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTherapy #CARTinChina #RelapsedLymphoma #RefractoryLymphoma #FollicularLymphoma #MantleCellLymphoma #Immunotherapy #CancerRevolution #AdvancedCancerCare #CD19Targeting #CancerHope #CancerCare #ChineseHospitals #GlobalHealth #CancerSurvivors #CARTSuccess #MedicalInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Global CAR-T Products on the Market and BCMA-Targeted CAR-T Products
Global CAR-T Products on the Market
CAR-T
Globally Approved BCMA-Targeted CAR-T Products
– Multiple Myeloma
Multiple Myeloma